Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757411 | 0.85 | KMT2A (0.48) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL4063599 | 0.84 | CYP2C19 (0.44) | MAPTKMT2AKCNN4KIF11CYP2C19 | |
| SCHEMBL5513060 | 0.81 | MAPT (0.44) | MAPTKMT2AKCNN4HTTCYP2C19 | |
| SCHEMBL10779190 | 0.79 | CES1 (0.53) | CYP2C19HIF1ACHRM1CHRM4CHRM5 | |
| SCHEMBL17449652 | 0.78 | CYP1A2 (0.41) | MAPTKMT2AKIF11CYP2C19HIF1A | |
| SCHEMBL2699401 | 0.78 | MAPT (0.48) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL27792551 | 0.78 | KCNN4 (0.43) | KMT2AKCNN4CYP2C19HIF1ACHRM1 | |
| SCHEMBL13946506 | 0.76 | MAPT (0.55) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL3837958 | 0.76 | MAPT (0.55) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL4030430 | 0.76 | MAPT (0.55) | MAPTKMT2AKCNN4HTTCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-8592475-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | MAPT 3673/4885KMT2A 3290/4885KCNN4 2842/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | MAPT 1827/4885KMT2A 1660/4885KCNN4 4587/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | MAPT 3788/4885KMT2A 3119/4885KCNN4 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.